BioRegenx, Inc. reported a significant decline in financial performance for the fiscal year ending December 31, 2025, with net sales of $1.85 million, a 21% decrease from $2.34 million in 2024. The company experienced a 28% drop in gross sales, which fell from $2.60 million to $1.86 million. Despite the decrease in sales, the cost of sales also decreased by 49%, resulting in a gross profit of $1.50 million, down 9% from the previous year. The net loss for the year was $1.54 million, a substantial improvement compared to a net loss of $23.05 million in 2024, reflecting a 93% reduction in losses.
The company underwent significant structural changes, including a merger with Findit, Inc. on March 8, 2024, which resulted in a change of control and a name change to BioRegenx, Inc. Following the merger, the company executed a 16-for-1 reverse stock split and plans to implement a 1-for-25 reverse split to attract institutional investors. Additionally, BioRegenx acquired DocSun Biomedical Holdings, Inc. in January 2024, enhancing its product offerings in contactless diagnostic technologies.
Operationally, BioRegenx's subsidiaries, including Microvascular Health Solutions and NuLife Sciences, have been focusing on product development and market expansion. The company reported a total of six full-time employees and eight independent contractors as of December 31, 2025. The company’s revenue from U.S. customers accounted for approximately 93% of total revenue, indicating a strong domestic market presence. However, the company is also looking to expand internationally, which remains a key focus area for future growth.
The filing highlighted ongoing challenges, including product-related issues that affected distributor engagement and sales activity. The company is transitioning its sales strategy towards online marketplaces, which may impact revenue consistency and customer acquisition costs. BioRegenx also faces significant debt obligations, with $522,500 in notes payable currently in default, raising concerns about its ability to continue as a going concern. The management is actively seeking additional financing to support operations and growth initiatives.
Looking ahead, BioRegenx anticipates continued losses and recognizes the need for substantial capital to fund its operations. The company is exploring various financing options, including a proposed follow-on public offering, but acknowledges the uncertainty surrounding the availability of such financing. The management's ability to execute its strategic plans will be critical in determining the company's future performance and stability.
About BIOREGENX, INC.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.